Effectiveness and Safety of Continuing or Stopping Aspirin in Treating Chronic Subdural Hematoma Without Surgery A Randomized Trial

What this Trial Is About

This trial investigates the safety and effectiveness of continuing versus stopping aspirin in patients undergoing conservative treatment for chronic subdural hematoma cSDH, a condition common in older adults often caused by minor head injuries. The study aims to resolve uncertainties about aspirin management in this group, as continuing aspirin may increase bleeding risk while stopping it might cause blood clots. This randomized clinical trial addresses an important gap, as current guidelines lack consensus on aspirin use during conservative care for cSDH. Participants receive standard conservative treatment for cSDH and are randomly assigned to either continue taking aspirin at 100 mg daily or to stop aspirin during treatment. Both groups follow the same non-surgical care plan. This trial does not involve surgery but focuses on medical management and monitoring over six months. The study compares outcomes between the aspirin continuation and discontinuation groups to inform better treatment decisions. During the study, participants will be closely monitored for changes in their subdural hematoma, neurological status, and any complications. Assessments include brain imaging, functional and cognitive tests, quality of life questionnaires, and tracking of cardiovascular events and adverse effects over six months. Researchers will measure hematoma recurrence or progression as the primary outcome and also evaluate disability levels, need for surgery, mortality, and other health events to understand the impact of aspirin use in conservative cSDH treatment.

Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma